[Clinicopharmacological studies with pindolol following intravenous and oral administration].

PubWeight™: 0.80‹?›

🔗 View Article (PMID 1032575)

Published in Adv Clin Pharmacol on January 01, 1976

Authors

W H Aellig

Articles by these authors

beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol (1976) 2.17

A new technique for recording compliance of human hand veins. Br J Clin Pharmacol (1981) 1.80

Blood levels of practolol following intravenous administration. Br J Pharmacol (1970) 1.61

Isoprenaline antagonism and duration of action in exercise induced tachycardia of three -adrenoceptor blocking drugs: pindolol, LF 17-895 and propranolol. Br J Pharmacol (1973) 1.35

Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. Int J Clin Pharmacol Biopharm (1977) 1.19

Venoconstrictor effect of dihydroergotamine in superficial hand veins. Eur J Clin Pharmacol (1974) 1.15

The influence of beta-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia. Br J Clin Pharmacol (1982) 1.15

[Peripheral circulatory effects of ergotamine, dihyroergotamine and 1-methylergotamine on the innevated, perfused hindlimb of the o]. Helv Physiol Pharmacol Acta (1967) 1.11

Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations. Br J Clin Pharmacol (1982) 1.08

Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity. Br J Clin Pharmacol (1985) 1.08

The action of intravenous oxprenolol, practolol, propranolol and sotalol on acute exercise tolerance in angina pectoris: the effect on heart rate and the electrocardiogram. Postgrad Med J (1970) 1.03

Duration of action and plasma levels of beta-adrenoceptor blocking drugs. Arch Int Pharmacodyn Ther (1980) 0.95

Prolonged action of pindolol. Br Med J (1973) 0.94

Use of a linear variable differential transformer to measure compliance of human hand veins in situ [proceedings]. Br J Clin Pharmacol (1979) 0.91

Intravenous diazepam in minor oral surgery. Further studies. Br Dent J (1970) 0.91

Clinical pharmacology of pindolol. Am Heart J (1982) 0.91

The effect of graded doses of practolol on the tachycardia induced by isoprenaline, Valsalva's manoeuvre and exercise. Br J Pharmacol (1970) 0.86

Investigation of the venoconstrictor effect of 8' hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man. Eur J Clin Pharmacol (1984) 0.84

Cardiac effects of adrenaline and felypressin as vasoconstrictors in local anaesthesia for oral surgery under diazepam sedation. Br J Anaesth (1970) 0.83

Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. Br J Clin Pharmacol (1986) 0.83

Investigations with beta-adrenoceptor blocking drugs in healthy volunteers. Acta Med Scand Suppl (1977) 0.82

A new technique for recording compliance of human hand veins. 1981. Br J Clin Pharmacol (2004) 0.82

Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed. Br J Pharmacol (1969) 0.82

Methods for studying drug effects on superficial human veins. Methods Find Exp Clin Pharmacol (1985) 0.81

Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. Eur J Clin Pharmacol (1991) 0.81

Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers. Eur J Clin Pharmacol (1978) 0.81

A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet. Eur J Clin Pharmacol (1981) 0.79

Influence of ergot compounds on compliance of superficial hand veins in man. Postgrad Med J (1976) 0.78

Studies on the venoconstrictor effect of ergot compounds in man. Triangle (1975) 0.78

Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration. Eur J Clin Pharmacol (1986) 0.78

Activity and duration of action of pindolol and alprenolol compared in healthy volunteers. Eur J Clin Pharmacol (1978) 0.77

Direct effects of vasoactive substances on superficial human veins in vivo. Int Angiol (1986) 0.76

Experiments with pindolol (Visken) in healthy volunteers. Med J Aust (1977) 0.76

Vasovagal faint in the supine position. Br Med J (1970) 0.75

Contrasts between pindolol and propranolol concentration-response relationships. Br J Clin Pharmacol (1985) 0.75

[Effect of ergot alkaloids on venous tonus determined in superficial hand veins in situ]. Cardiology (1976) 0.75

Agonists and antagonists of 5-hydroxytryptamine on venomotor receptors. Adv Neurol (1982) 0.75

The acute exercise test for the preliminary evaluation of beta-receptor blocking drugs in angina pectoris. Br J Pharmacol (1969) 0.75

Influence of pizotifen and ergotamine on the venoconstrictor effect of 5-hydroxytryptamine and noradrenaline in man. Eur J Clin Pharmacol (1983) 0.75

Clinical pharmacology of beta-adrenoceptor blocking drugs possessing partial agonist activity, with special reference to pindolol. J Cardiovasc Pharmacol (1983) 0.75

Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets. Eur J Clin Pharmacol (1982) 0.75

Clinical pharmacological studies with the long-acting beta-adrenoceptor blocking drug bopindolol. J Cardiovasc Pharmacol (1986) 0.75